Recent News

Nemus’s disruptive Glaucoma drug is likely to take market share at favorable pricing

Midtown Partners releases an initiating coverage report on Nemus Bioscience Inc. (NMUS). The report issues a Strong Buy rating with a price target of $2.48 (200%+ upside). Analysts Alec Jaslow and William Relyea believe NB1111, NMUS’s lead compound, is likely to have a competitive advantage over competing Glaucoma drugs given it may reduce intraocular pressure […]

Re-commercialization Proceeds with Some Delay

Midtown Partners releases an update note on Hemispherx Biopharma (HEB). The note reiterates a Strong Buy rating with a slightly lowered price target of $0.96 (500+% upside). Analysts Alec Jaslow and William Relyea expect recent news bode well for the stock:  two-year contract renewal with Armada Health, progress with Ampligen, and the recent news on […]

Restart of Alferon production should drive revenues and earnings in the medium-term

Midtown Partners initiates coverage of Hemispherx Biopharma (HEB) with a Strong Buy rating and a price target of $1.40 (500+% upside). Analysts Alec Jaslow and William Relyea believe the company’s Alferon N Injection drug has potential to take market share from current treatments for Refractory/Recurring HPV genital warts with its advantages which include less side […]

Midtown Partners Initiates Coverage of NanoViricides with a Strong Buy – High Risk Rating.

Midtown Partners initiates coverage of NanoViricides, Inc with a Strong Buy rating with a price target of $5.30. Analysts Alec Jaslow and William Relyea believe the company has a unique platform technology that targeting a number of large market viral diseases, especially important is Complicated Hospitalized Influenza.